ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1697

Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE

Anne Troldborg1, Mads Lamm Larsen1, Erik J.M. Toonen2, Lisa Hurler3, Zoltan Prohaszka3, László Cervenak3, Annette Gudmann Hansen4 and Steffen Thiel4, 1Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 2Hycult Biotech, Arnhem-Nijmegen, Netherlands, 3Semmelweis University, Budapest, Hungary, 4Aarhus University, Aarhus, Denmark

Meeting: ACR Convergence 2022

Keywords: complement, innate immunity, Lupus nephritis, Nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous research have demonstrated several of the lectin pathway (LP) proteins change with disease activity and specific SLE manifestations[2].

Traditionally, when diagnosing SLE or assessing disease activity, measurement of low C3 or C4 are used as proxies for complement activation [3]. However, measurement of C3 and C4 does not differentiate which complement pathway initiated the activation [1, 4].

C1-esterase inhibitor (C1inh) is one of the key regulators of the complement system. C1inh is the exclusive inhibitor of the active CP enzymes C1r and C1s [5], and the major inhibitor of active LP enzymes MASP-1 and MASP-2 [6]. A possible way of assessing complement activation through a specific pathway is by measuring activated enzymes complexed with C1inh in plasma, as these complexes only exist after complement enzyme activation.

Our aim was to investigate specific activation of the complement system through the LP or the CP in SLE by measuring the protein complexes MASP1/C1inh (LP specific activation) and C1s/C1inh (CP specific activation) in relation to disease activity and lupus nephritis (LN).

Methods: A cross sectional cohort of 150 patients with SLE fulfilling the 1997 ACR classification criteria for SLE were included. Disease manifestations and disease activity using SLEDAI-2K was assessed at inclusion. Fifty blood donors were used as controls. Both C1s/C1inh and MASP1/C1inh complexes were measured in all samples using two newly developed sandwich ELISAs (C1s/C1inh: cat# HK399; MASP1/C1inh: Cat#3001, Hycult Biotech, Uden, The Netherlands).

Results: When comparing SLE patients to controls, we observed a lower concentration in plasma of MASP1/C1inh (p< 0.01), whereas no difference was observed regarding C1s/C1inh (fig. a1 and b1).

C1s/C1inh concentrations were significantly increased in active SLE patients (SLEDAI >6) compared to SLE patients with low disease activity (SLEDAI < 6, p< 0.01) and C1s/C1inh concentrations correlated with SLEDAI score (r=0.285, p< 0.01) (fig. a2 and a3). C1s/C1inh concentrations were not significantly increased in SLE patients with active LN compared to non-active LN (p=0.09) (fig.a4).

MASP1/C1inh plasma concentrations were not associated with disease activity (p=0.11), and we did not observe a significant correlation with disease activity (r=0.12, p=0.13) (fig.b2 and b3). In active LN, plasma concentrations of MASP1/C1inh were significantly elevated compared to non-active LN (p=0.02) (fig. b4). No difference was observed between different classes of LN for neither MASP1/C1inh nor C1s/C1inh (p=0.143 and p=0.254, respectively) (fig. 2).

Conclusion: Our data support that the general complement activation seen in active SLE is associated with activation of the CP of complement activation. However, activation of the LP might be more specific to particular disease manifestations like LN.

Our findings warrant further research into activation of the specific complement pathways in relation to specific disease manifestations in SLE.

Supporting image 1

Figure 1. Measurements of plasma concentrations of C1s in complex with C1-inhibitor (C1s/C1inh) (a1-a4) and MASP1 in complex with C1-inhibitor (MASP1/C1inh) (b1-b4) in Systemic Lupus Erythematosus (SLE) patients and controls. A1 and b1 show measurements of SLE patients versus controls. A2 and b2 show measurements in SLE patients with active disease (SLEDAI >6) versus low disease activity (SLEDAI<6). A3 and b3 show correlation analysis between measurements and SLEDAI score in SLE patients. A4 and b4 show measurements in SLE patients with active lupus nephritis (LN) versus non-active LN.

Supporting image 2

Figure 2. Measurements of plasma concentrations of MASP1 in complex with C1-inhibitor (MASP1/C1inh) and C1s in complex with C1-inhibitor (C1s/C1inh) in non-active and different classes of active lupus nephritis. Although concentrations of activated proteins were elevated in active nephritis, the observed differences were not statistically significant. LN=Lupus Nephritis.


Disclosures: A. Troldborg, None; M. Larsen, None; E. Toonen, Hycult Biotech; L. Hurler, None; Z. Prohaszka, None; L. Cervenak, None; A. Hansen, None; S. Thiel, None.

To cite this abstract in AMA style:

Troldborg A, Larsen M, Toonen E, Hurler L, Prohaszka Z, Cervenak L, Hansen A, Thiel S. Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/measurements-of-specific-activation-through-the-lectin-or-classical-pathway-of-complement-in-patients-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/measurements-of-specific-activation-through-the-lectin-or-classical-pathway-of-complement-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology